707 related articles for article (PubMed ID: 26633291)
21. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
22. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
24. JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.
Cornez I; Yajnanarayana SP; Wolf AM; Wolf D
Mol Cell Endocrinol; 2017 Aug; 451():88-96. PubMed ID: 28131742
[TBL] [Abstract][Full Text] [Related]
25. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
26. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
27. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
28. JAK-STAT signaling pathway in non-infectious uveitis.
Su Y; Tao T; Liu X; Su W
Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
[TBL] [Abstract][Full Text] [Related]
29. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
[TBL] [Abstract][Full Text] [Related]
31. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
32. Dynamics and non-canonical aspects of JAK/STAT signalling.
Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
[TBL] [Abstract][Full Text] [Related]
33. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.
O'Shea JJ; Plenge R
Immunity; 2012 Apr; 36(4):542-50. PubMed ID: 22520847
[TBL] [Abstract][Full Text] [Related]
34. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.
Raychaudhuri SK; Raychaudhuri SP
Curr Opin Rheumatol; 2017 Jul; 29(4):311-316. PubMed ID: 28394822
[TBL] [Abstract][Full Text] [Related]
35. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.
Gadina M; Johnson C; Schwartz D; Bonelli M; Hasni S; Kanno Y; Changelian P; Laurence A; O'Shea JJ
J Leukoc Biol; 2018 Sep; 104(3):499-514. PubMed ID: 29999544
[TBL] [Abstract][Full Text] [Related]
36. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus.
Heim MH
J Recept Signal Transduct Res; 1999; 19(1-4):75-120. PubMed ID: 10071751
[TBL] [Abstract][Full Text] [Related]
37. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
38. Janus kinase inhibitors in autoimmune diseases.
O'Shea JJ; Kontzias A; Yamaoka K; Tanaka Y; Laurence A
Ann Rheum Dis; 2013 Apr; 72 Suppl 2(0 2):ii111-5. PubMed ID: 23532440
[TBL] [Abstract][Full Text] [Related]
39. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
40. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
